IRIS
FERRARO, Giuseppa
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.479
EU - Europa 1.270
AS - Asia 264
AF - Africa 1
Continente sconosciuto - Info sul continente non disponibili 1
Totale 3.015
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.476
SE - Svezia 397
IE - Irlanda 352
CN - Cina 230
IT - Italia 98
UA - Ucraina 95
DE - Germania 72
FR - Francia 59
FI - Finlandia 54
PL - Polonia 52
GB - Regno Unito 42
IN - India 21
BE - Belgio 18
AT - Austria 17
RU - Federazione Russa 8
VN - Vietnam 7
CA - Canada 3
IR - Iran 2
JP - Giappone 2
BG - Bulgaria 1
CH - Svizzera 1
DK - Danimarca 1
ES - Italia 1
EU - Europa 1
LV - Lettonia 1
NO - Norvegia 1
TH - Thailandia 1
TR - Turchia 1
ZA - Sudafrica 1
Totale 3.015
Salva come PNG Salva come JPEG
Città #
Dublin 352
Chandler 309
Nyköping 205
Jacksonville 196
Ashburn 118
Beijing 91
Ann Arbor 63
New York 61
Dearborn 58
Warsaw 52
Cambridge 51
Princeton 51
Medford 49
Des Moines 42
Messina 38
Boardman 34
Jinan 25
Woodbridge 22
Brussels 18
San Mateo 17
Vienna 17
Lancaster 16
Pune 16
Shenyang 14
Wilmington 13
Tianjin 12
Nanjing 11
Hebei 10
Zhengzhou 10
Houston 8
Dong Ket 7
Grammichele 6
Guangzhou 6
Ningbo 6
Augusta 5
Changsha 5
Fort Washington 5
Taizhou 5
Fuzhou 4
Haikou 4
Helsinki 4
Lanzhou 4
Leawood 4
Washington 4
Auburn Hills 3
Brockport 3
Catania 3
Hangzhou 3
Hyderabad 3
Jiaxing 3
London 3
Milan 3
Monmouth Junction 3
Nanchang 3
Norwalk 3
Seattle 3
Taiyuan 3
Tappahannock 3
Trepuzzi 3
Anagni 2
Bremen 2
Brooklyn 2
Falls Church 2
Hefei 2
Los Angeles 2
Novokuznetsk 2
Saint Petersburg 2
Acireale 1
Ardabil 1
Changle 1
Chengdu 1
Ciampino 1
Clearwater 1
Copenhagen 1
Cupertino 1
Edinburgh 1
Fairfield 1
Hillsdale 1
Jeffries 1
Johannesburg 1
Kemerovo 1
Kumamoto 1
Las Vegas 1
Montreal 1
Montréal 1
Mountain View 1
Mumbai 1
Oslo 1
Riva 1
Rüsselsheim 1
Santa Clara 1
Simi Valley 1
Stephentown 1
Taby 1
Tehran 1
Toronto 1
Zurich 1
Totale 2.139
Salva come PNG Salva come JPEG
Nome #
Prognostic value of methlylenetetrahydrofolate reductase (MTHFR), thymidylate synthase (TS) promoter, and p53 codon 72 variants and survival in advanced non-small cell lung cancer (NSCLC). 116
A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): old successes and future perspectives 101
Nab-paclitaxel and trastuzumab combination: A promising approach for neoadjuvant treatment in HER2-positive breast cancer 89
Androgen Receptor (AR), E-Cadherin, and Ki-67 as emerging targets and novel prognostic markers in triple-negative breast cancer (TNBC) patients 86
NSCLC and HER2: between lights and shadows 82
zd1839"iressa" in heavily pretreated patients with advaned/metastatic non-small cell lung cancer(NSCLC):assessment of tolerability and the clinical benefit 80
Beta=interferon in the treatment of 14 patie nts with advanced colorectal carcinoma. J Exp Pathol. 1987 Summer;3(4):603-5. No abstract available. PMID: 3454807 [PubMed - indexed for MEDLINE] 76
Is the adenocarcinoma subtype a predictor of response to Pemetrexed in patients with non small cell lung cancer? Our preliminary data. 75
Efficacy of nab-paclitaxel plus trastuzumab in a long-surviving heavily pretreated HER2-positive breast cancer patient with brain metastases 73
Is the adenocarcinoma subtype a predictor of response to Pemetrexed in patients with non small cell lung cancer? Our preliminary data 73
Preliminary study of pre-metastatic niche (PMN) in nonmetastatic nodes for the assessment of metastasis risk in breast cancer (BC). 73
ZD 1839 IRESSA IN HEAVILY PRETREATED PATIENTS WITH ADVANCED/METASTATIC NON SMALL CELL LUNG CANCER:ASSESSMENT OF TOLERABILITY AND CLINICAL BENEFIT 70
Etoposide, l-leucovorin and fluorouracil (ELF) regimen in metastatic gastric cancer: A phase II study 66
Impact of integrated treatments on patient management in solid tumors: from diagnosis to palliative care. 66
Gemcitabine (GEM) and cisplatin (CIS) in advanced/metastatic transitional cell carcinoma (TCC) of bladder:phase II study 66
A new method for titration of oral transmucosal fentanyl citrate (OTFC) starting dose in cancer patients. 61
A PHASE II STUDY (21 DAY REGIMEN) OF GEMCITABINE AND CISPLATIN IN TRANSITIONAL CELL CARCINOMA OF BLADDER 61
Metastasis risk assessment in breast cancer (BC): a preliminary study of pre-metastatic niche (PMN) in nonmetastatic nodes 60
Epidermal growth factor receptor (EGFR) G719C mutation as new determinant of long term survival and response in patients with non small cell lung cancer treated with erlotinib: 60
Androgen receptor (AR), E-cadherin, and Ki-67 as prognostic markers in triple-negative breast cancer (TNBC). 60
Etoposide, l-leucovorin and fluorouracil (ELF) regimen in metastatic gastric cancer: a phase II study. J Chemother. 1999 Feb;11(1):74-7. PMID: 10078785 [PubMed - indexed for MEDLINE] 60
Safety and activity of trastuzumab-containing therapies for the treatment of metastatic breast cancer: our long-term clinical experience (GOIM study) 58
Predicting sensitivity of non small cell lung cancer to gefitinib and erlotinib: is there still a role for clinical factors ? 58
Paclitaxel and cisplatin in patients with recurrent and metastatic head and neck squamous cell carcinoma. 57
Ruolo del Trastuzumab nel Trattamento Adiuvante del Carcinoma Mammario Operabile. 57
Safety of trastuzumab, alone or in combination, in elderly patients with HER2-positive breast cancer: A 5-year case series. 56
Cigarette smoking habit does not reduce the benefit from first line trastuzumab-based treatment in advanced breast cancer patients 54
Induction chemotherapy with paclitaxel and cisplatin to concurrent radiotherapy and weekly paclitaxel in the treatment of loco-regionally advanced, stage IV (M0), head and neck squamous cell carcinoma. Mature results of a prospective study. 54
Central nervous system involvement in ALK-rearranged NSCLC: promising strategies to overcome crizotinib resistance 54
Incidence and preferential localizations of bone metastases: biomolecolar and clinical implications. 53
Role of MTHFR polymorphisms as predictive markers of acute toxicity during 5-fluorouracil based chemotherapy for colorectal cancer: Preliminary data. 52
null 52
Effectiveness of the combination therapy with lisinopril, ivabradine and multivitamin supplementation in anthracycline-induced severe cardiotoxicity 52
Neoplasie della testa collo nell’ anziano 51
Early Breast Cancer HER2 positivo in postmenopausa: strategia terapeutica adiuvante 51
Current knowledge and future directions on bisphosphonate-related osteonecrosis of the jaw in cancer patients 50
Correlation between serum magnesium levels and skin toxicity during cetuximab treatment in squamous cell carcinoma of head and neck cancer (SCCHN): the role of weekly intravenous magnesium supplementation. 49
New biomarkers to predict response to pemetrexed-based chemotherapy in non small cell lung cancer: from 5,10-methylenetetrahydrofolate reductase promises to miRNAs revolution. 48
Role of Androgen Receptor (AR), Ki 67 and E-cadherin as prognostic markers in Triple Negative Breast Cancer (TNBC) 47
Pegylated liposomal doxorubicin and gemcitabine in the front-line treatment of recurrent/metastatic breast cancer: a multicentre phase II study. 46
Ruolo di Trastuzumab nella terapia adiuvante del carcinoma mammario operabile. 46
RANDOMISED PHASE II TERTIARY CHEMOPREVENTION TRIAL FOR COLORECTAL ADENOMA IN 24 PATIENTS WITH COLORECTAL CANCER TREATED WITH CELECOXIB 43
Correction: Androgen Receptor (AR), E-cadherin, and Ki-67 as emerging targets and novel prognostic markers in Triple-Negative Breast Cancer (TNBC) patients 43
Uncommon breast metastatic site and eribulin responsiveness in a heavily pretreated patient 42
SAFETY OF PEGILATED LIPOSOMAL DOXORUBICIN AND GEMCITABINE IN ELDERLY WOMEN (>65 YEARS)WITH LOCALLY ADVANCED OR METASTATIC BREAST CANCER 41
Safety of trastuzumab-containing therapies in elderly women with metastatic breast cancer. 41
Temozolamide plus oral vinorelbine in the treatment of brain metastases from solid tumours in heavily pre- treated patients. 41
Pegylated liposomal doxorubicin in combination with gemcitabine in elderly women with locally advanced or metastatic breast cancer: safety and activity results of our clinical experience. 41
null 37
Invecchiamento e cancro. 36
null 33
Risk evaluation in breast cancer: a preliminary study of pre-metastatic niche in 252 lymphnodes 29
null 22
Pre-metastatic niche identification in node negative breast cancer to assess metastasis risk. Pathological and clinical implications 19
The risk of toxicities from trastuzumab, alone or in combination, in an elderly breast cancer population. 13
Totale 3.080
Salva come PNG Salva come JPEG
Categoria #
all - tutte 9.816
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 9.816
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201921 0 0 0 0 0 0 0 0 0 0 1 20
2019/2020431 65 20 10 12 3 60 49 60 8 68 64 12
2020/2021442 37 5 105 44 32 44 17 25 15 39 53 26
2021/2022412 2 66 10 11 14 6 23 9 5 99 57 110
2022/20231.137 87 118 49 105 83 104 18 88 444 2 29 10
2023/2024301 18 50 15 27 16 124 30 17 0 4 0 0
Totale 3.080